Does gabapentin increase the seizure threshold?

Does Gabapentin Increase Seizure Threshold?

Yes, gabapentin increases the seizure threshold and demonstrates proven efficacy in reducing seizure frequency when used as adjunctive therapy for refractory partial epilepsy. 1

Evidence for Seizure Threshold Elevation

Direct Experimental Evidence

• Intraventricular gabapentin administration in rats significantly delays the onset of generalized tonic-clonic seizures induced by flurothyl, with seizures occurring at 338.0 ± 89.9 seconds in gabapentin-treated animals versus 295.8 ± 58.8 seconds in controls (p=0.049). 2

• Acute administration of a single therapeutic dose of gabapentin increases seizure threshold across all age groups studied, from newborn to adult animals, in flurothyl inhalation models. 3

• The threshold-raising effect occurs without significant changes in plasma gabapentin concentrations across different ages, suggesting a direct central nervous system mechanism. 3

Clinical Efficacy in Reducing Seizure Frequency

Gabapentin demonstrates Level A evidence for adjunctive treatment of refractory partial seizures in adults, with four Class I studies establishing efficacy at doses ranging from 600 to 1800 mg/day. 1

• The 50% responder rate (patients achieving ≥50% seizure reduction) is 1.89 times higher with gabapentin versus placebo (95% CI 1.40 to 2.55), based on meta-analysis of six trials involving 1206 participants. 4, 5

• Dose-response analysis shows 25.3% of patients respond to gabapentin 1800 mg/day compared to 9.7% on placebo, representing a 15.5% absolute increase in response rate. 4, 5

• At the 1200 mg/day dose, one Class I study reported a 56% median reduction in seizure frequency compared to placebo. 1

Pediatric Populations

Gabapentin is effective for refractory partial seizures in children, with Level A evidence supporting its use alongside lamotrigine, oxcarbazepine, and topiramate. 1

• In pediatric patients aged 3–12 years receiving 25–35 mg/kg/day, the response ratio was statistically significantly better (-0.146) compared to placebo (-0.079). 6

• Chronic gabapentin treatment following status epilepticus in immature animals reduces spontaneous seizure frequency, improves pathology scores, and decreases aggressiveness without long-term adverse effects on cognitive processes. 3

Important Caveats and Safety Considerations

Seizure Worsening in Specific Populations

Gabapentin can paradoxically worsen myoclonic seizures in patients with generalized epilepsy syndromes, particularly Lennox-Gastaut syndrome. 1

• Case reports document worsening of myoclonic seizures when gabapentin is used in mixed seizure disorders or idiopathic generalized epilepsy. 1

• No Class I or II evidence supports gabapentin use in Lennox-Gastaut syndrome, and case series show potential for seizure exacerbation. 1

Withdrawal Seizure Risk

Abrupt discontinuation of gabapentin can precipitate increased seizure frequency or status epilepticus. 6

• In placebo-controlled epilepsy studies, 0.6% of gabapentin-treated patients (3/543) developed status epilepticus versus 0.5% on placebo (2/378). 6

• Across all epilepsy studies, 1.5% of patients (31/2074) experienced status epilepticus, though adequate historical data are lacking to determine if this rate differs from untreated populations. 6

Tolerability Profile

Gabapentin is generally well-tolerated with a discontinuation rate of 1.05 times placebo (95% CI 0.74 to 1.49), indicating no significant difference in treatment withdrawal. 4, 5

• Common adverse effects include somnolence (RR 1.93), dizziness (RR 2.43), ataxia (RR 2.01), and fatigue (RR 1.95) compared to placebo. 4, 5

• The discontinuation rate due to adverse events ranged 3–11.5% in Class I studies, with somnolence, ataxia, and fatigue being the most common reasons. 1

Practical Dosing Considerations

Initiation at 900 mg/day in a single day causes more dizziness than a 3-day titration schedule, supporting gradual dose escalation. 1

• No therapeutic serum level range has been identified for gabapentin, and blood level monitoring is not routinely indicated. 1

• Gabapentin demonstrates no significant drug interactions with other antiepileptic drugs, as concomitant AED serum levels remain unchanged. 1

Limitations of Evidence

All reviewed trials were of relatively short duration (7–12 weeks) and provide no evidence for long-term efficacy beyond three months. 4, 5

• Results cannot be extrapolated to monotherapy or to other epilepsy types beyond refractory partial seizures. 4, 5

• Gabapentin used as monotherapy demonstrates inferior efficacy compared to other antiepileptic drugs for established epilepsy. 7